Carisma Therapeutics Inc (Nasdaq: CARM), a US-based clinical stage biopharmaceutical company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug application (IND) of CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy for the treatment of solid tumours that overexpress human epidermal growth factor receptor 2 (HER2).
The company has received a Study May Proceed notification from the FDA and is expected to start a phase one study in the coming months and to treat the first patient in the first half of 2024.
The Phase 1 study for CT-0525 is designed to assess the safety, tolerability, and the manufacturing feasibility of CT-0525. This study will enrol participants with locally advanced (unresectable) or metastatic solid tumours overexpressing HER2 whose disease has progressed on standard approved therapies. The study will consist of two cohorts: Cohort 1 will receive IV administration of up to 3 billion CAR-positive cells, while Cohort 2 will receive IV administration of CT-0525 of up to 10 billion CAR-positive cells.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment